Cwm LLC Raises Stock Position in Enanta Pharmaceuticals, Inc. $ENTA

Cwm LLC raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 22.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,464 shares of the biotechnology company’s stock after buying an additional 3,879 shares during the period. Cwm LLC owned approximately 0.10% of Enanta Pharmaceuticals worth $162,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE purchased a new position in Enanta Pharmaceuticals in the first quarter valued at about $36,000. Farther Finance Advisors LLC grew its holdings in Enanta Pharmaceuticals by 11,558.0% in the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,779 shares during the last quarter. MetLife Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at $72,000. Corton Capital Inc. purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at $77,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth $88,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENTA has been the subject of several research reports. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $14.00 to $20.00 in a research note on Wednesday, October 1st. HC Wainwright started coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They set a “buy” rating and a $20.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, October 8th. Westpark Capital raised their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, September 30th. Finally, JMP Securities raised their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.83.

Enanta Pharmaceuticals Price Performance

ENTA opened at $10.86 on Friday. The stock has a market capitalization of $232.17 million, a price-to-earnings ratio of -2.51 and a beta of 0.89. The business has a 50-day moving average of $9.65 and a two-hundred day moving average of $7.75. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. Equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.